• Explore /
  • Poster
  • / Non-myeloablative allogeneic blood or marrow transplantation (AlloBMT) with post-transplant cyclophosphamide (PTCy) for peripheral T-cell lymphoma (PTCL): Improved outcomes with peripheral blood (PB) allografts and increased total body irradiation (TBI) to 400 cGV.

Non-myeloablative allogeneic blood or marrow transplantation (AlloBMT) with post-transplant cyclophosphamide (PTCy) for peripheral T-cell lymphoma (PTCL): Improved outcomes with peripheral blood (PB) allografts and increased total body irradiation (TBI) to 400 cGV.

Abstract Poster

Authors

Cole Sterling

Cole Harris Sterling

The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD

Cole Harris Sterling , Michael Sang Hughes , Hua-Ling Tsai , Ephraim Joseph Fuchs , Kathryn Yarkony , Ravi Varadhan , Douglas Edward Gladstone , Lode J. Swinnen , Richard J. Jones , Nina D. Wagner-Johnston , Richard F. Ambinder

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Track

Hematologic Malignancies

Sub Track

Allogenic Stem Cell Transplantation

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 7047)

DOI

10.1200/JCO.2022.40.16_suppl.7047

Abstract #

7047

Poster Bd #

278

Abstract Disclosures

Similar Posters

First Author: Henry Jacob Conter

First Author: N. Pemmaraju

First Author: Ian W. Flinn

First Author: Larry D. Anderson, Jr